Catalist debutant SPCH aims to be one-stop pain shop

Singapore

THE domestic market is Singapore Paincare Holdings (SPCH)'s only nerve centre. But the company has Malaysia and Indonesia in its expansion crosshairs.

SPCH treats pain from the neck to the back and leg, as well as from cancer. It made its Catalist debut on Thursday, opening unchanged from its IPO price of S$0.220.

It rose as high as S$0.235 in intraday trading, but ended the day at S$0.210 with 4.7 million shares changing hands.

SPCH, which operates two specialist clinics and four medical clinics in the city state, wants to become a one-stop pain shop. It is eager to include…

A NEWSLETTER FOR YOU

Friday, 8.30 am

SGSME

Get updates on Singapore's SME community, along with profiles, news and tips.

Sign Up